Overall Rating


(3.4/5) Neutral

Pfizer (PFE)

Price*: $15.67 | Dividend: $1.28 | Dividend Yield: 8.17%

Recommendation Info
We downgraded this stock from the "Recommended" list on 11/12/08, at a price of 16.77.
Dividend Stock Ratings Breakdown Dividend Stock Ratings Breakdown
1. Relative Strength   What's This?

Stock is slightly underperforming.
2. Overall Yield Attractiveness   What's This?

Stock's dividend yield is attractive.
3. Dividend Reliability   What's This?

This rating is directly related to the length and consistency of a company's dividend payouts.
4. Dividend Uptrend   What's This?

Dividend payouts are consistent, but increases small.
5. Earnings Growth   What's This?

Earnings estimates have been cut slightly.
Price and Dividend Info Price and Dividend Info
Pfizer (PFE)
Previous Day's Closing Price*
$15.67
Annual Stock Dividend
$1.28
Current Dividend Yield
8.17%

Recent Headlines Recent Headlines

Dividend Stock Profile & Recommendation Profile & Recommendation


Company Profile Company Profile

Pfizer (PFE) - pharmaceutical name that has struggled with lack of new blockbuster drugs lately. A dividend has been paid since 1901, and raised each year since 1968. Its Pharmaceutical segment offers products for cardiovascular and metabolic diseases, such as Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; and Exubera, the inhaled human insulin therapy for glycemic control. Its products for central nervous system disorders include Zoloft for various disorders; Geodon/Zeldox, a psychotropic agent; Aricept for Alzheimer's disease; and Lyrica for adjuctive therapy for adults with partial onsent epileptic seizures. This segment also offers Celebrex for osteoarthritis, adult rheumatoid arthritis, acute pain, menstrual pain, and familial adenomatous polyposis; Zithromax for bacterial infections; Vfend for serious and potentially fatal fungal infections, esophageal candidiasis, and blood stream infections in non-neutropenic patients; Zyvox for bacterial infections; and Viagra for erectile dysfunction; and Detrol for overactive bladder. In addition, it offers Camptosar, a therapy for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; Genotropin for various growth disorders; and Zyrtec for allergies and hives. The company was founded in 1849 and is headquartered in New York, New York.

Dividend Stock Recommendation - Neutral Recommendation

Based on our rating criteria, this stock has achieved a "Neutral" rating. Stocks with a neutral rating are considered mediocre investments in terms of expected price growth and dividend payments.

Stock Notes Stock Notes

This large cap stock does not make an attractive dividend stock investment at this time.

* Stock price reflects previous day's closing price. All stock quotes on this website should be considered as having a 24-hour delay.

** Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.